Prognostic factors and indications for treatment of Waldenström's Macroglobulinemia

Research output: Contribution to journalReview article

Abstract

Waldenström's Macroglobulinemia (WM) is characterized by the presence of an IgM monoclonal protein regardless of its size, 10% or more bone marrow infiltration by small lymphocytes with a plasmacytoid or plasma cell differentiation. These cells usually have the following markers: IgM+, CD5, CD10, CD19+, CD20+ and CD23. Chronic lymphocytic leukemia as well as other lymphoproliferative disorders such as mantle cell, marginal zone and mucosa-associated lymphoid tissue (MALT) lymphoma must be excluded. Weakness or fatigue from anemia, fever, night sweats, or weight loss represent the most common symptoms. Hepatosplenomegaly may be a major feature. Anemia, thrombocytopenia, hyperviscosity or peripheral neuropathy may be prominent features. Systemic amyloidosis, renal insufficiency and cryoglobulinemia may also be seen. WM must be differentiated from smoldering Waldenström's Macroglobulinemia (SWM) which is an intermediate disease state characterized by an IgM protein ≥3 g/dL and/or a bone marrow containing ≥10% bone marrow lymphoplasmacytic infiltration but no end-organ damage such as symptomatic anemia, constitutional symptoms, hyperviscosity, symptomatic hepatosplenomegaly or lymphadenopathy.

Original languageEnglish (US)
Pages (from-to)179-186
Number of pages8
JournalBest Practice and Research: Clinical Haematology
Volume29
Issue number2
DOIs
StatePublished - Jun 1 2016

Fingerprint

Waldenstrom Macroglobulinemia
Immunoglobulin M
Anemia
Bone
Bone Marrow
Infiltration
Cryoglobulinemia
Marginal Zone B-Cell Lymphoma
Lymphoproliferative Disorders
Lymphocytes
Sweat
Peripheral Nervous System Diseases
Amyloidosis
B-Cell Chronic Lymphocytic Leukemia
Plasma Cells
Thrombocytopenia
Renal Insufficiency
Fatigue
Weight Loss
Cell Differentiation

Keywords

  • IgM monoclonal gammopathy
  • Indolent lymphoma
  • Lymphoplasmacytic lymphoma
  • Lymphoproliferative disorder

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Clinical Biochemistry

Cite this

Prognostic factors and indications for treatment of Waldenström's Macroglobulinemia. / Kyle, Robert A.; Ansell, Stephen Maxted; Kapoor, Prashant.

In: Best Practice and Research: Clinical Haematology, Vol. 29, No. 2, 01.06.2016, p. 179-186.

Research output: Contribution to journalReview article

@article{5ef9d88952354857bcaaad78013a8908,
title = "Prognostic factors and indications for treatment of Waldenstr{\"o}m's Macroglobulinemia",
abstract = "Waldenstr{\"o}m's Macroglobulinemia (WM) is characterized by the presence of an IgM monoclonal protein regardless of its size, 10{\%} or more bone marrow infiltration by small lymphocytes with a plasmacytoid or plasma cell differentiation. These cells usually have the following markers: IgM+, CD5−, CD10−, CD19+, CD20+ and CD23−. Chronic lymphocytic leukemia as well as other lymphoproliferative disorders such as mantle cell, marginal zone and mucosa-associated lymphoid tissue (MALT) lymphoma must be excluded. Weakness or fatigue from anemia, fever, night sweats, or weight loss represent the most common symptoms. Hepatosplenomegaly may be a major feature. Anemia, thrombocytopenia, hyperviscosity or peripheral neuropathy may be prominent features. Systemic amyloidosis, renal insufficiency and cryoglobulinemia may also be seen. WM must be differentiated from smoldering Waldenstr{\"o}m's Macroglobulinemia (SWM) which is an intermediate disease state characterized by an IgM protein ≥3 g/dL and/or a bone marrow containing ≥10{\%} bone marrow lymphoplasmacytic infiltration but no end-organ damage such as symptomatic anemia, constitutional symptoms, hyperviscosity, symptomatic hepatosplenomegaly or lymphadenopathy.",
keywords = "IgM monoclonal gammopathy, Indolent lymphoma, Lymphoplasmacytic lymphoma, Lymphoproliferative disorder",
author = "Kyle, {Robert A.} and Ansell, {Stephen Maxted} and Prashant Kapoor",
year = "2016",
month = "6",
day = "1",
doi = "10.1016/j.beha.2016.08.014",
language = "English (US)",
volume = "29",
pages = "179--186",
journal = "Best Practice and Research in Clinical Haematology",
issn = "1521-6926",
publisher = "Bailliere Tindall Ltd",
number = "2",

}

TY - JOUR

T1 - Prognostic factors and indications for treatment of Waldenström's Macroglobulinemia

AU - Kyle, Robert A.

AU - Ansell, Stephen Maxted

AU - Kapoor, Prashant

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Waldenström's Macroglobulinemia (WM) is characterized by the presence of an IgM monoclonal protein regardless of its size, 10% or more bone marrow infiltration by small lymphocytes with a plasmacytoid or plasma cell differentiation. These cells usually have the following markers: IgM+, CD5−, CD10−, CD19+, CD20+ and CD23−. Chronic lymphocytic leukemia as well as other lymphoproliferative disorders such as mantle cell, marginal zone and mucosa-associated lymphoid tissue (MALT) lymphoma must be excluded. Weakness or fatigue from anemia, fever, night sweats, or weight loss represent the most common symptoms. Hepatosplenomegaly may be a major feature. Anemia, thrombocytopenia, hyperviscosity or peripheral neuropathy may be prominent features. Systemic amyloidosis, renal insufficiency and cryoglobulinemia may also be seen. WM must be differentiated from smoldering Waldenström's Macroglobulinemia (SWM) which is an intermediate disease state characterized by an IgM protein ≥3 g/dL and/or a bone marrow containing ≥10% bone marrow lymphoplasmacytic infiltration but no end-organ damage such as symptomatic anemia, constitutional symptoms, hyperviscosity, symptomatic hepatosplenomegaly or lymphadenopathy.

AB - Waldenström's Macroglobulinemia (WM) is characterized by the presence of an IgM monoclonal protein regardless of its size, 10% or more bone marrow infiltration by small lymphocytes with a plasmacytoid or plasma cell differentiation. These cells usually have the following markers: IgM+, CD5−, CD10−, CD19+, CD20+ and CD23−. Chronic lymphocytic leukemia as well as other lymphoproliferative disorders such as mantle cell, marginal zone and mucosa-associated lymphoid tissue (MALT) lymphoma must be excluded. Weakness or fatigue from anemia, fever, night sweats, or weight loss represent the most common symptoms. Hepatosplenomegaly may be a major feature. Anemia, thrombocytopenia, hyperviscosity or peripheral neuropathy may be prominent features. Systemic amyloidosis, renal insufficiency and cryoglobulinemia may also be seen. WM must be differentiated from smoldering Waldenström's Macroglobulinemia (SWM) which is an intermediate disease state characterized by an IgM protein ≥3 g/dL and/or a bone marrow containing ≥10% bone marrow lymphoplasmacytic infiltration but no end-organ damage such as symptomatic anemia, constitutional symptoms, hyperviscosity, symptomatic hepatosplenomegaly or lymphadenopathy.

KW - IgM monoclonal gammopathy

KW - Indolent lymphoma

KW - Lymphoplasmacytic lymphoma

KW - Lymphoproliferative disorder

UR - http://www.scopus.com/inward/record.url?scp=84994545408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994545408&partnerID=8YFLogxK

U2 - 10.1016/j.beha.2016.08.014

DO - 10.1016/j.beha.2016.08.014

M3 - Review article

VL - 29

SP - 179

EP - 186

JO - Best Practice and Research in Clinical Haematology

JF - Best Practice and Research in Clinical Haematology

SN - 1521-6926

IS - 2

ER -